|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
Murtaza Khorakiwala
|
|
gptkbp:country
|
gptkb:India
|
|
gptkbp:focus
|
gptkb:biotechnology
gptkb:Antibiotics
Vaccines
Research and development
|
|
gptkbp:foundedBy
|
Habil Khorakiwala
|
|
gptkbp:foundedYear
|
1960
|
|
gptkbp:hasResearchCenter
|
gptkb:India
gptkb:UK
US
|
|
gptkbp:headquartersLocation
|
gptkb:Mumbai
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Wockhardt Ltd.
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:ISIN
|
INE049B01025
|
|
gptkbp:listedOn
|
gptkb:Bombay_Stock_Exchange
gptkb:National_Stock_Exchange_of_India
|
|
gptkbp:manufacturingFacilities
|
gptkb:India
gptkb:Ireland
gptkb:UK
US
|
|
gptkbp:market
|
Global
|
|
gptkbp:netIncome
|
INR -286 crore (2023)
|
|
gptkbp:notableProduct
|
gptkb:Wosulin
gptkb:Erythropoietin
gptkb:Rabies_vaccine
Biovac-B
G-CSF
COVID-19 vaccine (fill-finish for AstraZeneca)
|
|
gptkbp:numberOfEmployees
|
~7,900
|
|
gptkbp:parentCompany
|
Khorakiwala family
|
|
gptkbp:products
|
Vaccines
Biopharmaceuticals
Pharmaceutical formulations
|
|
gptkbp:regulatoryApprovals
|
gptkb:US_FDA
gptkb:TGA_(Australia)
gptkb:EMA_(Europe)
gptkb:MHRA_(UK)
|
|
gptkbp:revenue
|
INR 2,913 crore (2023)
|
|
gptkbp:servesArea
|
Worldwide
|
|
gptkbp:stockExchange
|
gptkb:NSE
BSE
|
|
gptkbp:stockSymbol
|
532300
WOCKPHARMA
|
|
gptkbp:subsidiary
|
Wockhardt Bio AG
Wockhardt UK Ltd.
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.wockhardt.com/
|
|
gptkbp:bfsParent
|
gptkb:Wockhardt_Hospital
|
|
gptkbp:bfsLayer
|
7
|